Managed Oncology

As the oncology pipeline continues to deliver innovative therapies, healthcare stakeholders are evolving their approaches to managing utilization, reimbursement, distribution, and patient access. HIRC’s Managed Oncology Service helps pharmaceutical organizations better understand these developments by examining oncology medication management, distribution trends, and stakeholder perspectives across the oncology ecosystem.

The service provides independent insights into a broad range of cancer therapies as follows:

Cancer Therapy Categories analyzed:

• Oncology Biosimilars & Brand Originators
• Immune Checkpoint Inhibitors
• CAR-T Cell Therapies
• Bispecific Antibodies
• Radioligand Therapy (RLT)
• 18+ Oral and IV Targeted Cancer types

For more information or to subscribe, contact Raymond Co.

HIRC employs a triangulated research methodology that combines primary survey research, in-depth stakeholder interviews, and secondary market analysis to provide a comprehensive understanding of healthcare stakeholder perspectives, market dynamics, and emerging industry trends.

Research includes perspectives from:

• Academic and Health System-based Cancer Centers
• Community Oncology Practices
• Commercial Health Plans
• Pharmacy Benefit Managers
• Medicare Advantage Plans

Subscribers can monitor emerging oncology market developments, better understand payer and provider perspectives, benchmark manufacturer engagement, and make more informed decisions regarding market access, customer engagement, and organizational planning.